<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3432">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636554</url>
  </required_header>
  <id_info>
    <org_study_id>APT.APS.001</org_study_id>
    <nct_id>NCT04636554</nct_id>
  </id_info>
  <brief_title>Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia</brief_title>
  <official_title>Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii, P. Aeruginosa or S. Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptive Phage Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptive Phage Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      Bacteriophage treatment in Covid-19 patients being treated with Anti-Microbials for Pneumonia&#xD;
      or Bacteremia/Septicemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment approach will be to make phage therapy available to institutions who care for&#xD;
      Covid-19 patients with bacterial co-infections due to A. baumannii, P. aeruginosa or S.&#xD;
      aureus. Patient bacterial isolates will be tested to determine phage susceptibility prior to&#xD;
      and during phage therapy.&#xD;
&#xD;
      The primary objectives are to determine the feasibility of developing, producing and&#xD;
      providing a personalized intravenous phage for Covid-19 patients who have pneumonia,&#xD;
      bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus and to evaluate the&#xD;
      safety of intravenous phage in Covid-19 patients along with anti-microbial treatment for&#xD;
      pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Covid19</condition>
  <condition>Bacteremia</condition>
  <condition>Septicemia</condition>
  <condition>Acinetobacter Baumannii Infection</condition>
  <condition>Pseudomonas Aeruginosa Infection</condition>
  <condition>Staph Aureus Infection</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phage Therapy</intervention_name>
    <description>Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Covid-19 patients with pneumonia or bacteremia/septicemia who have culture-confirmed&#xD;
             bacterial co-infection with A. baumannii, P. aeruginosa or S. aureus.&#xD;
&#xD;
          -  Patient provided informed and signed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient eligible for another APT sponsored trial.&#xD;
&#xD;
          -  Patient participating in another clinical trial at the same time or patients &lt; 4 weeks&#xD;
             from participating in an alternative investigational protocol/study&#xD;
&#xD;
          -  Patient with known allergy to infusion of phage products&#xD;
&#xD;
          -  Patients with a history of Meningitis or encephalitis at time of study entry, Primary&#xD;
             immune deficiency disease or tuberculosis or Stroke, transient ischemic attack (TIA),&#xD;
             or untreated deep vein thrombosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Robert J Hopkins, MD, MPH&amp;TM, FACP, FIDSA</last_name>
    <phone>240-367-4006</phone>
    <email>rhopkins@aphage.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Holland</last_name>
    <phone>202-391-8058</phone>
    <email>sholland@aphage.com</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Bacteriophage</keyword>
  <keyword>Phage</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Septicemia</keyword>
  <keyword>Acinetobacter</keyword>
  <keyword>baumannii</keyword>
  <keyword>Pseudomonas</keyword>
  <keyword>Aeruginosa</keyword>
  <keyword>Infection</keyword>
  <keyword>Staph</keyword>
  <keyword>Aureus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

